BR112016008267A2 - Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito - Google Patents
Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócitoInfo
- Publication number
- BR112016008267A2 BR112016008267A2 BR112016008267A BR112016008267A BR112016008267A2 BR 112016008267 A2 BR112016008267 A2 BR 112016008267A2 BR 112016008267 A BR112016008267 A BR 112016008267A BR 112016008267 A BR112016008267 A BR 112016008267A BR 112016008267 A2 BR112016008267 A2 BR 112016008267A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- isoforms
- lateral sclerosis
- amyotrophic lateral
- preventing
- Prior art date
Links
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 title abstract 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 title abstract 4
- 102000001708 Protein Isoforms Human genes 0.000 title abstract 4
- 108010029485 Protein Isoforms Proteins 0.000 title abstract 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSIÇÃO PARA PREVENIR OU TRATAR ESCLEROSE LATERAL AMIOTRÓFICA USANDO DUAS OU MAIS ISOFORMAS DE FATOR DE CRESCIMENTO DE HEPATÓCITO. A presente invenção refere-se a uma composição para prevenir ou tratar esclerose lateral amiotrófica, a composição contendo, como um princípio ativo, duas ou mais isoformas de um fator de crescimento de hepatócito (HGF) ou um polinucleotídeo que codifica as isoformas. A composição da presente invenção é usada para prevenir ou tratar eficazmente esclerose lateral amiotrófica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130126216 | 2013-10-22 | ||
PCT/KR2014/009971 WO2015060650A2 (ko) | 2013-10-22 | 2014-10-22 | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 |
KR1020140143377A KR101779775B1 (ko) | 2013-10-22 | 2014-10-22 | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016008267A2 true BR112016008267A2 (pt) | 2017-10-03 |
Family
ID=53386224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016008267A BR112016008267A2 (pt) | 2013-10-22 | 2014-10-22 | Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito |
Country Status (13)
Country | Link |
---|---|
US (1) | US10639351B2 (pt) |
EP (1) | EP3061457B1 (pt) |
JP (1) | JP6240337B2 (pt) |
KR (2) | KR101779775B1 (pt) |
CN (1) | CN105682676B (pt) |
AU (1) | AU2014337870B2 (pt) |
BR (1) | BR112016008267A2 (pt) |
CA (1) | CA2926607C (pt) |
ES (1) | ES2773305T3 (pt) |
HK (1) | HK1219873A1 (pt) |
MX (1) | MX2016005006A (pt) |
RU (1) | RU2639582C2 (pt) |
SG (1) | SG11201602452SA (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3046202B1 (fr) * | 2015-12-24 | 2017-12-29 | Snecma | Turboreacteur avec un moyen de reprise de poussee sur le carter inter-compresseurs |
CA3086046C (en) * | 2017-12-29 | 2023-02-21 | Helixmith Co., Ltd. | Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto |
JP7380670B2 (ja) * | 2018-07-17 | 2023-11-15 | ヘリックスミス カンパニー, リミテッド | Igf-1-暗号化dna作製物及びhgf-暗号化dna作製物を用いた神経病症治療 |
CN110577954A (zh) * | 2019-10-12 | 2019-12-17 | 北京万福来生物技术有限责任公司 | 突变的肝细胞生长因子基因及其应用 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0255320A3 (en) | 1986-07-28 | 1989-09-06 | Genzyme Corporation | Production of proteins in myeloma cells |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
NZ232813A (en) | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
CA2022752C (en) | 1989-08-11 | 1998-07-07 | Naomi Kitamura | Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
EP0539590B1 (en) | 1990-07-13 | 1999-03-31 | Snow Brand Milk Products Co., Ltd. | Plasmid containing dna which codes for the amino acid sequence of tcf-ii, transformed cell, and production of physiologically active substance by using the same |
US5661133B1 (en) | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
US7323297B1 (en) | 1992-04-03 | 2008-01-29 | The Regents Of The University Of California | Stabilized polynucleotide complexes and methods |
JP3680114B2 (ja) | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
US5652225A (en) | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
US6143714A (en) | 1994-10-24 | 2000-11-07 | Regeneron Pharmaceuticals, Inc. | Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons |
US20030148968A1 (en) | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
JP3927248B2 (ja) | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Hgf凍結乾燥製剤 |
WO1997007824A1 (fr) | 1995-08-29 | 1997-03-06 | Sumitomo Pharmaceuticals Co., Ltd. | Medicament comprenant le gene hgf |
US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
EA005157B1 (ru) | 1997-05-06 | 2004-12-30 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Методы и составы для лечения сердечной недостаточности и вентрикулярной коррекции путем доставки in vivo ангиогенных трансгенов |
WO1999036103A1 (en) | 1998-01-16 | 1999-07-22 | Mcgill University | Prevention and treatment of neuropathy by hepatocyte growth factor |
JPH11246433A (ja) | 1998-03-03 | 1999-09-14 | Sumitomo Pharmaceut Co Ltd | 心筋梗塞治療剤 |
WO1999045775A1 (en) | 1998-03-09 | 1999-09-16 | St. Elizabeth's Medical Center | Compositions and methods for modulating vascularization |
US20040228834A1 (en) | 1998-03-09 | 2004-11-18 | Jeffrey Isner | Compositions and methods for modulating vascularization |
EP1555033A3 (en) | 1998-03-13 | 2005-08-17 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
DE69925113T2 (de) | 1998-03-13 | 2006-01-19 | Wyeth | Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung |
US7276359B1 (en) | 1998-03-13 | 2007-10-02 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
WO2000007615A1 (fr) | 1998-08-05 | 2000-02-17 | Sumitomo Pharmacueticals Co., Ltd. | Preparations destinees a l'administration d'un facteur de croissance des hepatocytes |
KR20000046969A (ko) | 1998-12-31 | 2000-07-25 | 이선경 | 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더 |
CA2356701C (en) | 1999-10-29 | 2011-02-15 | Ryuichi Morishita | Gene therapy for diabetic ischemic disease |
JP2003513942A (ja) | 1999-11-05 | 2003-04-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インビボ遺伝子送達による心血管疾患を処理するための技術および組成物 |
ATE530197T1 (de) | 2000-06-27 | 2011-11-15 | Anges Mg Inc | Medizinische zusammensetzungen zur angiogenese- therapie |
AU2001286221B2 (en) | 2000-09-13 | 2006-09-28 | Chugai Seiyaku Kabushiki Kaisha | Remedies for ischemic diseases |
JP5442173B2 (ja) | 2000-09-14 | 2014-03-12 | 敏一 中村 | 筋萎縮性側索硬化症治療剤 |
US20030176347A1 (en) | 2003-05-14 | 2003-09-18 | Toshikazu Nakamura | Remedies for amyotrophic lateral sclerosis |
CN1150035C (zh) | 2000-12-21 | 2004-05-19 | 中国人民解放军军事医学科学院放射医学研究所 | 一种重组质粒及其在疾病防治中的应用 |
CA2433936A1 (en) | 2001-01-23 | 2002-08-22 | Boston Scientific Corporation | Localized myocardial injection method for treating ischemic myocardium |
KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
WO2004060059A2 (en) | 2002-12-23 | 2004-07-22 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
US20050164208A1 (en) | 2004-01-22 | 2005-07-28 | Paul Poulin | Storage of genetic information |
KR100833612B1 (ko) | 2004-12-29 | 2008-05-30 | 에프씨비파미셀 주식회사 | 간엽 간세포로부터 분화된 신경세포를 유효성분으로함유하는 신경계 질환 치료용 약학 조성물 |
AU2006244639A1 (en) | 2005-03-31 | 2006-11-16 | Mytogen, Inc. | Treatment for heart disease |
US20070212390A1 (en) | 2005-09-22 | 2007-09-13 | Ludwig Institute For Cancer Research | Protease-resistant forms of VEGF-D, method of making and method of use |
KR20080082629A (ko) | 2005-11-10 | 2008-09-11 | 리셉터 바이오로직스 인크 | 간세포 성장인자 인트론 융합 단백질 |
US20090130761A1 (en) | 2006-05-17 | 2009-05-21 | Yoshiyuki Koyama | Freeze-Dried Product for Introducing Nucleic Acid, Oligonucleic Acid or Derivative Thereof |
WO2007142651A1 (en) | 2006-06-09 | 2007-12-13 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Methods and compositions for the treatment of neuropathy |
ES2520044T3 (es) | 2007-03-30 | 2014-11-11 | The Cleveland Clinic Foundation | SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos |
ATE543507T1 (de) | 2007-11-07 | 2012-02-15 | Ono Pharmaceutical Co | Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung |
US20090202606A1 (en) | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
CA2720611C (en) | 2008-04-09 | 2016-07-12 | Viromed Co., Ltd. | Lyophilized dna formulations for enhanced expression of plasmid dna |
RU2413524C1 (ru) | 2009-07-31 | 2011-03-10 | Общество с ограниченной ответственностью "КриоЦентр" | Способ лечения психических и неврологических расстройств |
DK2516648T3 (en) | 2009-12-23 | 2018-02-12 | Curna Inc | TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF |
WO2012025925A1 (en) | 2010-08-24 | 2012-03-01 | Rappaport Family Institute For Research In The Medical Sciences | Methods of improving transplantation using sdf-1alpha |
WO2013037521A1 (en) | 2011-09-16 | 2013-03-21 | Medical Research Council | Modified hgf-1k1 polypeptide |
WO2013037520A1 (en) | 2011-09-16 | 2013-03-21 | Glaxo Group Limited | Modified hgf-1k1 polypeptide |
JP2013129661A (ja) * | 2013-02-20 | 2013-07-04 | Toshiichi Nakamura | 筋萎縮性側索硬化症治療剤 |
-
2014
- 2014-10-22 MX MX2016005006A patent/MX2016005006A/es active IP Right Grant
- 2014-10-22 CN CN201480058075.3A patent/CN105682676B/zh active Active
- 2014-10-22 RU RU2016119116A patent/RU2639582C2/ru active
- 2014-10-22 BR BR112016008267A patent/BR112016008267A2/pt not_active Application Discontinuation
- 2014-10-22 SG SG11201602452SA patent/SG11201602452SA/en unknown
- 2014-10-22 CA CA2926607A patent/CA2926607C/en active Active
- 2014-10-22 US US15/030,999 patent/US10639351B2/en active Active
- 2014-10-22 AU AU2014337870A patent/AU2014337870B2/en active Active
- 2014-10-22 JP JP2016546724A patent/JP6240337B2/ja active Active
- 2014-10-22 ES ES14856385T patent/ES2773305T3/es active Active
- 2014-10-22 KR KR1020140143377A patent/KR101779775B1/ko active IP Right Grant
- 2014-10-22 EP EP14856385.1A patent/EP3061457B1/en active Active
-
2016
- 2016-07-06 HK HK16107864.0A patent/HK1219873A1/zh unknown
-
2017
- 2017-08-31 KR KR1020170110892A patent/KR101860452B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
RU2639582C2 (ru) | 2017-12-21 |
EP3061457A2 (en) | 2016-08-31 |
KR20150047108A (ko) | 2015-05-04 |
CA2926607A1 (en) | 2015-04-30 |
EP3061457A4 (en) | 2017-06-07 |
KR101779775B1 (ko) | 2017-09-21 |
SG11201602452SA (en) | 2016-05-30 |
EP3061457B1 (en) | 2020-01-22 |
CA2926607C (en) | 2018-10-23 |
AU2014337870B2 (en) | 2019-11-28 |
KR20170104129A (ko) | 2017-09-14 |
JP6240337B2 (ja) | 2017-11-29 |
US10639351B2 (en) | 2020-05-05 |
AU2014337870A1 (en) | 2016-05-05 |
JP2016534149A (ja) | 2016-11-04 |
RU2016119116A (ru) | 2017-11-28 |
HK1219873A1 (zh) | 2017-04-21 |
ES2773305T3 (es) | 2020-07-10 |
CN105682676B (zh) | 2020-10-23 |
MX2016005006A (es) | 2016-07-14 |
US20160250291A1 (en) | 2016-09-01 |
CN105682676A (zh) | 2016-06-15 |
KR101860452B1 (ko) | 2018-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017020999A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
BR112015021999A2 (pt) | inibidores de indoleamina 2,3-dioxigenase (ido) | |
BR112015032595A2 (pt) | inibidores de ido | |
PH12015502028A1 (en) | Ido inhibitors | |
BR112015022417A2 (pt) | métodos e composições para inibição de proteínas contendo bromodomínio | |
CO7111303A2 (es) | Compuestos de microarn y métodos de modulación de la actividad de mir-21 | |
BR112016021648A2 (pt) | novos compostos | |
MX2020001258A (es) | Moduladores del factor del complemento b. | |
MX366875B (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
PH12016501160A1 (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
PH12016502062A1 (en) | Compositions and methods for modulating completent factor b expression | |
EA201491970A1 (ru) | Циклические мостиковые простые эфиры в качестве ингибиторов dgat1 | |
BR112014031866A2 (pt) | Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano | |
BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
BR112016011472A2 (pt) | tienopirimidinas como inibidores de mknk1 e mknk2 | |
BR112018073944A2 (pt) | uso de uma composição. | |
MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
BR112016008267A2 (pt) | Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito | |
BR112014010594A2 (pt) | terapia genética para neuropatia diabética empregando um isoforma do hgf | |
BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
BR112016000338A8 (pt) | composto enriquecido em deutério de fórmula estrutural i, composição farmacêutica, e usos de um composto | |
BR112016021656A2 (pt) | inibidores das vias de sinalização de wnt | |
EA201500736A1 (ru) | Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов | |
BR112018077440A2 (pt) | uma composição para uso no tratamento de infecção de rotavírus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B25D | Requested change of name of applicant approved |
Owner name: HELIXMITH CO., LTD (KR) |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |